These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12797385)

  • 1. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.
    Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL
    J Chemother; 2003 Apr; 15(2):113-7. PubMed ID: 12797385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of linezolid against anaerobic bacteria.
    Behra-Miellet J; Calvet L; Dubreuil L
    Int J Antimicrob Agents; 2003 Jul; 22(1):28-34. PubMed ID: 12842325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
    Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
    Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
    Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
    Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria.
    Yagi BH; Zurenko GE
    Anaerobe; 1997 Oct; 3(5):301-6. PubMed ID: 16887605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
    Shore KP; Pottumarthy S; Morris AJ
    N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
    Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait.
    Al Sweih N; Mokaddas E; Jamal W; Phillips OA; Rotimi VO
    J Chemother; 2005 Dec; 17(6):607-13. PubMed ID: 16433190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
    Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
    J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
    Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
    J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
    Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
    Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
    Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
    Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
    Credito KL; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4430-4. PubMed ID: 15504874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT; Bryskier A
    Antimicrob Agents Chemother; 2005 Jan; 49(1):408-13. PubMed ID: 15616322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial susceptibility of clinical isolates of aerobic gram-positive cocci and anaerobic bacteria in 2008].
    Yoshida I; Yamaguchi T; Kudo R; Fuji R; Takahashi C; Oota R; Kaku M; Kunishima H; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Fujita S; Matsuo S; Kono H; Asari S; Toyokawa M; Kusano N; Nose M; Horii T; Tanimoto A; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
    Jpn J Antibiot; 2012 Feb; 65(1):49-72. PubMed ID: 22808693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2149-52. PubMed ID: 15155214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.